Sectors
BioTech, Environmental, Entertainment
Headquarters
Dallas, TX, USA
CEO
Ben Lamm
Colossal Biosciences shares returned -19.43%, with $63.93M in secondary bids, offers, and transactions activity over the last 90 days, according to PM Insights' institutional secondary market data.
Register today to view the full report, with more in-depth details and analytics
Latest funding round
XXXXX
XX-XX-XXXX
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
Low
XXXXX
Colossal Biosciences is leading the development of innovative genetic technologies to revive extinct species, restore ecosystems, and tackle biodiversity loss, aiming to secure a sustainable future for both humanity and the planet.
Business Partnerships
Targeted Impact
Colossal Biosciences aims to revive extinct species, restore ecosystems, enhance conservation, and fight global biodiversity loss.
Who Will Benefit?
Wildlife conservationists, genetic researchers, academic institutions, and biotechnology investors benefit from Colossal Biosciences.
What Comes Next?
Colossal Biosciences is pushing mammoth de-extinction, reviving the thylacine, and expanding gene-editing platforms worldwide.
No items found.
.png)
Colossal Biosciences shares returned -19.43%, with $63.93M in secondary bids, offers, and transactions activity over the last 90 days, according to PM Insights' institutional secondary market data.
No items found.
No items found.
Ready to see it in action?
Schedule a demo with one of our experts
